Drug General Information (ID: DDI2N7JWP3)
Drug Name			Tetracosactide		Drug Info		Rubella virus vaccine		Drug Info
Drug Type		Small molecule				Vaccine
Therapeutic Class		Diagnostic Agents				Vaccine

Mechanism of Tetracosactide-Rubella virus vaccine Interaction (Severity Level: Moderate)
Antagonize the effect of vaccine/toxoid Click to Show/Hide Mechanism Graph
Drug Name		Tetracosactide				Rubella virus vaccine
Mechanism		Immunosuppressive effects				Vaccine or toxoid
Key Mechanism Factor 1
		Factor Name		Vaccine/toxoid
		Factor Description		The beneficial effects of the vaccine/toxinoid may be reduced, leading to a diminished or suboptimal immune response.
Mechanism Description		Antagonize the effect of Rubella virus vaccine when combined with Tetracosactide

Recommended Action
Management		In general, live attenuated vaccines should not be used in patients receiving immunosuppressive corticosteroid therapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored. The interval depends on the dosage and duration of corticosteroid therapy administered, but may be at least 3 months in most cases. Current local immunization guidelines should be consulted for recommendations. In patients who have recently been vaccinated, high-dose corticosteroid therapy should not be initiated for at least 2 weeks. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).

References
1	Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison's Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998).
2	Product Information. Attenuvax (measles virus vaccine, live, attenuated). Merck &amp Co, Inc, West Point, PA.
3	Product Information. Orimune (poliovirus vaccine, live, oral, trivalent). Lederle Laboratories, Philadelphia, PA.